SLQT
T3SelectQuote, Inc.
OverviewSelectQuote operates a technology-driven marketplace connecting seniors and families with insurance carriers. The Senior segment (49% of revenue) provides Medic
SelectQuote operates a technology-driven marketplace connecting seniors and families with insurance carriers. The Senior segment (49% of revenue) provides Medicare plans, while Healthcare Services (43%) offers prescription drug delivery through SelectRx. The Life segment (8%) sells term and final expense policies. They primarily serve American seniors, partnering with major national insurance carriers to distribute diverse health and life products.
- What They Do (Plain English & Analogies)
- SelectQuote acts as a high-tech 'personal shopper' for insurance and a 'concierge pharmacy' for seniors. Imagine a travel booking site like Expedia, but instead of flights, they use expert agents and data to help seniors find the best Medicare Advantage or Life insurance plans. Additionally, through their SelectRx brand, they act like a specialized pharmacy that pre-packages multiple medications into easy-to-use daily strips (like a high-end pill organizer service) to help patients with complex health needs stay on track with their prescriptions.
- Very Brief History
- Founded in 1999 and headquartered in Overland Park, Kansas, SelectQuote pioneered the direct-to-consumer insurance brokerage model. The company went public in May 2020. While historically focused on term life and Medicare distribution, it underwent a major strategic shift in 2021-2022 to launch Healthcare Services (SelectRx) to diversify its revenue and move toward a more recurring, cash-flow-positive business model.
- "Street Stereotype"
- SelectQuote is often viewed by investors as a 'high-beta' play on the Medicare Advantage market. The 'stereotype' is that the company is highly sensitive to the marketing budgets of big insurance carriers and regulatory changes from CMS. While respected for its technology and agent productivity, it has historically been dogged by concerns over high debt levels and the volatility of its 'Level 1' (LTV-based) accounting revenue.
- Subsidiaries On Linked In*
- SelectQuote Insurance Services, SelectRx, InsideResponse.
- New Customers / Segments They'Re Targeting
- SelectQuote is aggressively targeting 'Dual-Eligible' seniors (those qualified for both Medicare and Medicaid) and those requiring 'Special Needs Plans' (SNPs). In its Healthcare Services segment, it is gunning for 'poly-pharmacy' patients—seniors taking 10 or more medications—who represent the highest value and most stable revenue for the SelectRx pharmacy platform.
- How Key Themes May Help/Hurt
- The company benefits from the 'Aging of America' and the shift toward Medicare Advantage. However, it is currently being hurt by a 'tightening' theme in the insurance industry where carriers are prioritizing profitability over growth, leading to slashed marketing budgets. The 'PBM Reform' theme is a double-edged sword: while it creates reimbursement uncertainty (a $20M headwind in 2026), it also pushes the industry toward the 'cost-plus' pharmacy models that SelectRx is built to handle.
3 Main Long-Term Bull Details
- SelectRx is transforming the company from a one-time commission broker into a recurring-revenue healthcare provider with 20%+ revenue growth. 2) The new $415M credit facility extends debt maturities to 2031, significantly reducing near-term bankruptcy risk. 3) Industry-leading operational efficiency, evidenced by 39% EBITDA margins in their Senior segment during the most recent peak season.
3 Main Long-Term Bear Details
- Carrier Concentration Risk: A single national carrier's decision to cut marketing spend recently wiped $20M off their 2026 guidance. 2) Regulatory Pressure: CMS 'Advance Rate' notices for 2027 suggest lower payments to carriers, which usually trickles down as lower commissions for brokers like SLQT. 3) PBM Volatility: Unpredictable changes in drug reimbursement rates can cause sudden, material hits to pharmacy profitability.
- Competitors And Differentiation
- Primary competitors include GoHealth (GOCO), eHealth (EHTH), and Assurance IQ (owned by Prudential). SelectQuote differentiates itself through its 'SelectRx' integration, which creates a 'sticky' ecosystem; once a senior uses their pharmacy, they are much less likely to switch insurance brokers (33% recapture rate). They also claim a technology advantage that makes their agents 12% more productive than the industry average.
- Recent Performance & What The Market'S Focused On
- In Feb 2026, SLQT reported a strong Q2 with $537M in revenue (+12%), but the market is focused on a significant guidance cut. The company lowered its FY2026 EBITDA target to $90M-$100M (from a previous higher range) due to a $40M aggregate hit from PBM reimbursement changes and a major carrier slashing its marketing budget. Investors are closely watching if the company can hit its goal of $25M-$35M in positive operating cash flow despite these headwinds.
- Brands And Revenue Segments
- Brands: SelectQuote, SelectRx. Revenue Segments (Q2 2026): Senior (Medicare Advantage/Supplement) - $262M; Healthcare Services (SelectRx pharmacy) - $231M; Life (Term & Final Expense) - $44M; Auto & Home - (Minor contribution).
Bull / Bear DetailsAs of February 11, 2026, SelectQuote's investment case is a transition from high-growth volatility to a cash-flow-centric model. While external headwinds from c
Thesis
As of February 11, 2026, SelectQuote's investment case is a transition from high-growth volatility to a cash-flow-centric model. While external headwinds from carrier marketing cuts and PBM pricing adjustments have lowered near-term EBITDA guidance, the company's successful debt refinancing to 2031 and near-record 39% Senior margins demonstrate operational resilience. The bull case rests on SelectRx's path to profitability and a stabilized capital structure, though carrier-driven volatility and CMS rate pressures remain significant risks to the outlook.
Bull case
SelectQuote continues to demonstrate superior execution in its Senior segment, achieving near-record EBITDA margins of 39% despite a turbulent Medicare Advantage landscape. High agent productivity and a 33% customer recapture rate highlight the value of its technology platform. This operational efficiency allows the company to generate significant cash flow even when policy volume growth is modest, providing a stable foundation for the broader business.
The Healthcare Services segment, led by SelectRx, is pivoting from rapid member growth to margin expansion. A new multi-year PBM agreement with a 'guaranteed' rate structure significantly improves pricing visibility and mitigates reimbursement risks. Management's target of a $40M-$50M annualized EBITDA exit rate for FY26 suggests that SelectRx is becoming a major contributor to consolidated profitability and positive operating cash flow.
The recent $415M credit facility refinancing is a major catalyst, extending debt maturities to 2031 and removing immediate liquidity concerns. This provides the operational flexibility needed to navigate industry shifts and invest in high-return segments like Special Needs Plans. Furthermore, the company's focus on 'Cash EBITDA' and a projected $25M-$35M in operating cash flow for FY26 marks a critical turning point toward deleveraging.
Bear case
A significant risk is the reliance on national insurance carriers who can abruptly curtail marketing budgets, as evidenced by the recent $20M EBITDA headwind from a single partner's pullback. As carriers prioritize their own profitability amidst rising utilization and disappointing CMS rate notices, further pullbacks in third-party distribution spending could continue to pressure SelectQuote's revenue growth and lead acquisition costs in the Senior segment.
The Medicare Advantage market faces ongoing headwinds from CMS, with the 2027 preliminary rate notice failing to account for rising care costs. If final rates remain soft, carriers may further reduce benefits or exit markets, sustaining high plan termination levels which recently hit 7%. This macro environment creates persistent uncertainty for SelectQuote's primary revenue driver and could lead to higher churn or lower policy lifetime values.
While SelectRx shows promise, the segment still faces execution risks as it shifts focus toward 'extremely complex' patients and stabilizes its pharmacy workflow. Achieving the $40M-$50M EBITDA exit rate requires flawless management of drug reimbursement dynamics and pharmacy efficiency. Any failure to hit these profitability targets, or further unexpected shifts in PBM pricing models, could undermine the company's transition to a sustainable cash-flow profile.
Bull / Bear Case
- Bear Case
- The bear case for SelectQuote is defined by its extreme vulnerability to external partner decisions and regulatory shifts. The $40M aggregate reduction in FY2026 EBITDA guidance—driven by a single carrier's marketing pullback and PBM reimbursement changes—highlights a lack of control over its own financial destiny and significant concentration risk. With the CMS 2027 preliminary rates coming in lower than expected, there is a high probability that other national carriers will similarly curtail marketing spend to protect their own margins, leading to further downward revisions. Additionally, the Healthcare Services segment, while growing, remains susceptible to the volatile pharmacy reimbursement landscape, as evidenced by the recent $20M PBM headwind. Management's shift to emphasizing 'Cash EBITDA' may be viewed by skeptics as an attempt to mask disappointing GAAP results and repeated guidance cuts, keeping the stock in a 'show-me' penalty box for institutional investors.
- Bull Case
- SelectQuote's bull case is centered on its successful pivot from high-growth volatility to a sustainable, cash-flow-positive model. Despite external headwinds, the Senior segment achieved near-record 39% EBITDA margins, demonstrating the 'battle-tested' efficiency of its technology-driven marketplace. The Healthcare Services segment (SelectRx) remains a potent growth engine, with revenue up 26% and a new multi-year PBM agreement providing the pricing stability needed to reach a $40M-$50M EBITDA exit rate by fiscal year-end. Crucially, the recent $415M debt refinancing extends maturities to 2031, removing immediate liquidity concerns and providing the operational flexibility to navigate a disruptive Medicare Advantage environment. As carriers face rising utilization and plan terminations reach 7%, SelectQuote's role as a high-quality distribution partner becomes more vital, as seniors increasingly rely on their 'information advantage' to navigate complex benefit changes.
- More Compelling & Why
- The Bull Case is more compelling at the current valuation. While the $40M guidance cut is disappointing, the market's -17% post-earnings decline likely over-discounts this 'noisy' EBITDA hit while ignoring the transformative $415M debt refinancing. Extending maturities to 2031 significantly de-risks the bankruptcy thesis. With Senior margins at 39% and a clear path to $25M-$35M in positive operating cash flow, the fundamental floor is strengthening despite external carrier-driven volatility.
Key Factors
| Key Factor | Why It Matters | What To Watch | What It Signals | Where/How To Track | Free Alt Data | Paid Alt Data |
|---|---|---|---|---|---|---|
| SelectRx Annualized EBITDA Exit Rate ($40M-$50M Target) | Management has staked the Healthcare Services thesis on reaching a $40M-$50M annualized adjusted EBITDA exit rate by the end of fiscal 2026. This transition from growth-at-all-costs to profitability is critical for the company's valuation and cash flow story. | Quarterly Adjusted EBITDA for the Healthcare Services segment. To hit the $40M-$50M exit rate, quarterly EBITDA must trend toward $10M-$12.5M by Q4 FY2026. | Bullish if Healthcare Services EBITDA exceeds $8M in Q3 FY26; Bearish if membership growth stalls without a corresponding increase in segment profitability. | SEC Form 10-Q and 10-K filings, specifically the 'Segment Information' note in the financial statements. | Indeed/LinkedIn: Tracking job postings for pharmacists and pharmacy technicians in Kansas and other SelectRx hub locations to gauge operational scale. | Thinknum: Tracking SelectRx web traffic and pharmacy-specific job hiring trends. |
| FY2026 Operating Cash Flow ($25M-$35M Guidance) | With the new $415M credit facility, the company is pivoting to prioritize 'Cash EBITDA' and positive operating cash flow to deleverage. Meeting this guidance is essential to prove the business model is self-sustaining and can service the new 2031 debt. | Net cash provided by operating activities on the Consolidated Statement of Cash Flows. Watch for the gap between reported EBITDA and actual cash generated. | Bullish if cumulative operating cash flow exceeds $15M by the end of Q3 FY26; Bearish if the company remains cash-flow negative or if the $25M floor is lowered in future updates. | Quarterly earnings releases and SEC Form 10-Q filings. | SEC Filings: Monitor Form 4 filings for insider buying, which often precedes confidence in cash flow inflections. | Consumer Edge: Credit card data tracking insurance premium payments (though indirect, it can signal retention/recapture success). |
| CMS Final 2027 Medicare Advantage Rate Notice | The preliminary 2027 rates were described as 'disappointing' by management and carriers. The final notice determines carrier profitability and their subsequent marketing budgets for the upcoming Annual Enrollment Period (AEP), which directly impacts SelectQuote's Senior segment revenue and lead volume. | The final rate announcement from CMS, typically released in early April. Watch for the 'effective yield' or 'benchmark rate' change compared to the preliminary notice. | Bullish if the final rate is significantly higher than the preliminary notice (e.g., >1% improvement), signaling carriers may reinstate marketing budgets. Bearish if rates remain flat or decrease, likely leading to further marketing pullbacks. | CMS.gov press releases and the Federal Register; typically released on the first Monday of April. | KFF (Kaiser Family Foundation) analysis of Medicare Advantage rate trends; industry news on Modern Healthcare or Fierce Healthcare. | Visible Alpha: Consensus estimates for Medicare Advantage enrollment and carrier margin expectations. |
| Carrier Marketing Budget Reinstatement | The $20M guidance reduction was triggered by a single national carrier cutting its strategic marketing budget. Tracking whether this carrier (or others) restores spend is the primary indicator for Senior segment growth in FY2027. | Earnings transcripts from major carriers (UNH, HUM, CVS/Aetna). Look for mentions of 'third-party distribution,' 'marketing spend,' or 'customer acquisition costs' (CAC). | Bullish if major carriers signal a return to 'growth mode' for the 2027 AEP; Bearish if additional carriers announce similar 10-20% cuts to their external broker marketing budgets. | Quarterly earnings calls of UnitedHealth Group (UNH), Humana (HUM), and CVS Health (CVS). | Google Trends: Search volume for 'Medicare Advantage' and specific carrier names, which correlates with the effectiveness of carrier-funded marketing. | Pathmatics: Tracking digital ad spend by major insurance carriers to see if marketing budgets are being redirected or cut in real-time. |
| PBM 'Guaranteed' Rate Structure (GER) Compliance | A $20M EBITDA headwind was attributed to PBM reimbursement changes. The new multi-year agreement with a major PBM includes a 'guaranteed' rate structure (GER) intended to eliminate pricing volatility and stabilize SelectRx margins. | Healthcare Services gross margins. Management expects the new deal to provide 'increased visibility' and stability in drug reimbursement pricing starting in the second half of FY26. | Bullish if Healthcare Services gross margins expand by >200 bps sequentially; Bearish if reimbursement rates continue to fluctuate despite the new 'guaranteed' contract. | Management commentary during Q3 and Q4 FY26 earnings calls regarding 'PBM reimbursement stability.' | CMS National Average Drug Acquisition Cost (NADAC) database to track general trends in wholesale drug pricing vs. reimbursement. | IQVIA: Data on prescription volumes and reimbursement trends for complex chronic care medications. |
Key Reported Metrics
| Metric | Why It Matters | Last Period |
|---|---|---|
| Healthcare Services Revenue | Healthcare Services Revenue (SelectRx) is the growth engine for cash flow and profitability. Its momentum will be tested by PBM reimbursement dynamics and capacity deployment, impacting overall mix and long-term margin trajectory. | 26% |
| Senior Revenue | Senior Revenue drives the near-record EBITDA margins (39%) and cash flow generation. The next quarter will show if growth from MA policy volumes and agent productivity can offset marketing efficiency headwinds and help sustain profitability. | 2% |
| Total Revenue | Total revenue is the company's top-line and reflects the combined performance of Senior, Healthcare Services, and Life segments. In the next quarter, total revenue will indicate how the PBM headwind and carrier marketing pullback are pricing into demand and whether the earnings trajectory remains on track. | 12% |
Key QuestionsWill the final CMS 2027 Medicare Advantage rate notice in April trigger additional marketing budget cuts from carrier partners, or will SelectQuote's geographic
Will the final CMS 2027 Medicare Advantage rate notice in April trigger additional marketing budget cuts from carrier partners, or will SelectQuote's geographic and product pivots successfully mitigate the current $20M headwind?
- Question 2
Can the Healthcare Services segment (SelectRx) successfully transition to its $40M-$50M annualized EBITDA exit rate target by the end of fiscal 2026 under the new 'guaranteed' PBM rate structure?
- Question 3
Does the pivot to 'Cash EBITDA' and the $25M-$35M operating cash flow guidance provide enough of a valuation floor to offset investor concerns regarding the $40M aggregate reduction in reported FY2026 EBITDA guidance?
Earnings Transcript Summary
· 2026Q2 Earnings Call
| 3 Things Management Is Most Focused On | Call Takeaway & Tone | Prior Quarter'S Y/Y Growth By Segment | 3 Things Analysts Most Pressed On (And Mgmt Responses) | Revenue Segments |
|---|---|---|---|---|
| 1. Cash Flow and Profitability over Growth: Management is prioritizing 'Cash EBITDA' and operating cash flow (guided to $25M-$35M for FY26) as the primary measure of success, shifting away from pure volume growth. 2. Capital Structure Flexibility: The new $415M credit facility is a major focus, as it extends debt maturities to 2031, providing the 'operational flexibility' to navigate market volatility. 3. SelectRx Margin Expansion: Following a new multi-year PBM agreement, management is focused on stabilizing drug reimbursement pricing and improving the clinical value proposition to drive profitability in Healthcare Services. | Takeaway: The call centered on a 'noisy' quarter where strong operational performance (near-record 39% Senior margins) was overshadowed by a $40M aggregate guidance reduction due to external partner actions (PBM rates and a carrier marketing pullback). Despite the guidance cut, the core message was one of financial stabilization through a major debt refinancing and a pivot to positive free cash flow. Tone: Resilient but cautious; management expressed frustration with external volatility while maintaining high confidence in their 'battle-tested' operational model. | Senior: +1% Y/Y (Accelerated); Healthcare Services: +31% Y/Y (Decelerated); Life: +11% Y/Y (Decelerated). | 1. Carrier Marketing Budget Cuts: Analysts questioned the $20M EBITDA headwind caused by a single carrier's decision to cut marketing; Management responded that they have 'levers' to pivot marketing spend to other regions and high-value segments like Special Needs Plans (SNPs). 2. PBM Reimbursement Stability: Analysts pressed for details on the new PBM deal and its impact on the $20M headwind; Management explained the deal provides a 'guaranteed' rate structure (GER) that eliminates the risk of unexpected pricing updates. 3. CMS Advance Rate Notice: Analysts raised concerns about the soft 2027 preliminary rates; Management agreed the rates are low but argued that plan disruption actually increases the value of SelectQuote's marketplace as seniors seek help navigating changes. | Senior: +2% Y/Y ($262M); Healthcare Services: +26% Y/Y ($231M); Life: +9% Y/Y ($44M); Consolidated: +12% Y/Y ($537M). |
Transcript Tidbits
| About Expanding Eligible Market | About Competition | About The Broader Industry | Where Things Are Headed | Updates On Theme | Broader Themes Emerging | Bullish-Leaning Quotes (Short) | Bearish-Leaning Quotes (Short) | Hiring |
|---|---|---|---|---|---|---|---|---|
| SelectQuote is focusing on Special Needs Plans (SNPs) where carriers are looking to grow. They are leveraging their 50-state direct-to-consumer model to pivot marketing geographically and targeting 'extremely complex' seniors for SelectRx—specifically those with 3+ chronic conditions on 10+ medications. | The Term Life business faced 'increased competition' and marketing expense pressure. In the Medicare Advantage space, a national carrier's decision to cut marketing budgets impacted the entire third-party distribution landscape, including e-brokers and FMOs, forcing a more disciplined approach to lead acquisition. | The Medicare Advantage industry is seeing 'financial stress' due to rising utilization and care costs. Plan terminations reached 7% of total plans in force, compared to a historical average below 1%. Additionally, the CMS 2027 advanced rate notice was described as disappointing by carrier partners. | The company is pivoting to prioritize 'Cash EBITDA' and operating cash flow, guided to $25M-$35M for FY26. SelectRx is expected to reach an annualized adjusted EBITDA exit rate of $40M-$50M by the end of fiscal 2026. Debt maturities have been successfully extended to 2031 to provide 'operational flexibility.' | The | The industry is shifting toward 'cost-plus' PBM structures and 'guaranteed' rate structures (GER). There is also an emerging focus on using AI and modern technology to retrofit 'archaic' pharmacy workflows for better clinical outcomes and efficiency. | "Near-record senior EBITDA margins of 39%."; "Recapture rate which was 33% this year... even better result."; "New credit facility significantly extends our debt maturities to 2031." | "Carrier significantly cut their strategic marketing budget."; "Lower our fiscal 2026 guidance... $40 million aggregate impact."; "Preliminary rates don't reflect rising utilization and care costs." |
Notes
| Date | Comment | Comment Type | Comment Sentiment | Link | IS CHANGE | Price Reaction |
|---|---|---|---|---|---|---|
| 2026-02-05 | SelectQuote's Q2 results featured strong Senior margins and a critical $415 million debt refinancing. Despite a $40 million FY2026 guidance cut—driven by carrier marketing pullbacks and PBM headwinds—the market initially rewarded the improved balance sheet and cash flow outlook (+6.8%). However, the subsequent 17% decline indicates that long-term concerns regarding Medicare Advantage volatility and carrier partner stability now outweigh the initial refinancing optimism. | Earnings Transcript | Mixed | https://www.selectquote.com/investor-relations | False | +6.80% (vs SPY: +4.39%) |